Clinical-stage biopharmaceutical company Nuvalent, Inc. (Nasdaq:NUVL) announced on Monday the initiation of HEROEX-1, a Phase 1a/1b clinical trial for NVL-330.
NVL-330 is a novel HER2-selective inhibitor targeting HER2-altered non-small cell lung cancer (NSCLC) in pre-treated patients. HER2 alterations, including exon 20 mutations, are key oncogenic drivers in NSCLC with no approved TKIs for this patient population. NVL-330 aims to address this by maintaining activity against HER2 exon 20 mutations, limiting EGFR-related toxicities, and penetrating the brain to tackle metastases.
HEROEX-1 will evaluate NVL-330's safety, tolerability, recommended Phase 2 dose, pharmacokinetic profile and preliminary anti-tumor activity.
This trial involves a multicenter, open-label, dose-escalation and expansion study design. NVL-330's differentiated preclinical profile supports its potential efficacy in this clinical investigation.
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial
Turnstone Biologics announces strategic restructuring
Pfizer's TALZENNA plus XTANDI shows promise in prostate cancer treatment
GenesisCare UK selects RayStation for radiotherapy system upgrade
Boehringer Ingelheim and Circle Pharma collaborate on cancer treatment
Petauri launches medical communications platform Petauri Advance
Bayer and MOMA Therapeutics enter oncology collaboration
GBI Biomanufacturing agrees manufacturing collaboration with Allterum Therapeutics
MediLink enters clinical trial collaboration and supply agreement with Amgen